Login to Your Account

'Array' of Ph II Asthma Data Spurs Stock

By Marie Powers
Staff Writer

Wednesday, July 24, 2013

Shares of Array Biopharma Inc. hit a 52-week high of $7.20 Tuesday morning after the company reported positive findings from its randomized Phase II trial of oral CRTh2 antagonist ARRY-502 in mild to moderate persistent allergic asthma. The compound hit the primary endpoint – significant improvement in pre-bronchodilator forced expiratory volume in one second (FEV1), compared to placebo – across the study population and in a predefined Th2 biomarker subset that represented half of treated patients.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription